about header
Press Releases
Print Text Size
  • 5/6/09 1:40 pm EDT
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today outlined its plans for continued sustainable growth across each of its businesses, provided updates on anticipated near-term regulatory milestones, and shared new clinical data at its Analyst Day Meeting.

    more...
  • 4/22/09 8:55 am EDT
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that first-quarter revenue rose to $1.15 billion, compared with $1.10 billion in the same period a year ago, an increase of 4 percent. Including the $66 million impact of unfavorable currency exchange rates, revenue grew 10 percent in the first quarter.

    more...
  • 3/31/09 8:00 am EDT
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has entered into an agreement to acquire the worldwide rights to Campath® (alemtuzumab) from Bayer HealthCare, giving Genzyme primary responsibility for the development and commercialization of this potential break-though treatment for multiple sclerosis (MS). Bayer will continue to fund a portion of alemtuzumab’s development in MS and will retain an option to co-promote the product in MS upon approval.

    more...
  • 3/19/09 1:08 pm EDT
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the European Medicines Agency’s Committee for Human Medicinal Products (CHMP) has adopted a positive opinion for the marketing authorization of the new phosphate binder Renvela® (sevelamer carbonate) for use in patients with chronic kidney diseas

    more...
  • 3/2/09 4:23 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that it has received a complete response letter from the FDA regarding its application to market Lumizyme™ (alglucosidase alfa) for the treatment of Pompe disease.

    more...
  • 2/26/09 9:32 am EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the European Commission has approved the production of Myozyme® (alglucosidase alfa) at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. The product will be made commercially available immediately. Myozyme is the only approved treatment for Pompe disease, a progressively debilitating and often fatal inherited disorder.

    more...
  • 2/26/09 9:22 am EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Synvisc-One (hylan G-F 20), a product intended for the relief of pain associated with osteoarthritis (OA) of the knee. Synvisc-One is the only single-injection viscosupplement approved for the treatment of OA knee pain in the United States.

    more...
  • 2/20/09 1:45 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today reported that the Phase 2 clinical trial of its investigational oral therapy Genz-112638 for Gaucher disease type 1 met its primary endpoint.

    more...
  • 2/19/09 12:39 pm EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corporation (Nasdaq: GENZ) announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company’s variation to produce Myozyme® (alglucosidase alfa) at the 4000 liter (L) bioreactor scale at its manufacturing facility in Geel, Belgium. The positive CHMP opinion is the final step before formal approval to produce and market Myozyme manufactured at the 4000 L bioreactor scale in the European Union, Norway and Iceland.

    more...
  • 2/11/09 8:51 am EST
    CAMBRIDGE, Mass.--

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) today announced solid fourth-quarter revenue and earnings growth and provided guidance for 2009 that underscored its positive outlook for the year.

    more...
Contact Us
 

Media Resources

Tweets

Social Media

Business Wire NewsHQ℠
infoBox